PSU Profiles
Keywords
Last Name
Institution

Wafik El-Deiry

TitleProfessor
InstitutionCollege of Medicine
DepartmentMedicine
Address500 University Drive Hershey PA 17033

 Overview 
 overview
PREFERRED TITLE/ROLE:

Professor of Medicine, Chief, Hematology/Oncology, Rose Dunlap Division Chair in Hematology/Oncology, Associate Director for Translational Research, Cancer Institute

EDUCATION:

Fellowship, Medical Oncology, Johns Hopkins Hospital (Maryland) (1994) Residency, Internal Medicine, Johns Hopkins Hospital (Maryland) (1990) Internship, Internal Medicine, Johns Hopkins Hospital (Maryland) (1988) M.D., University of Miami School of Medicine (Florida) (1987)

NARRATIVE:

Dr. El-Deiry is committed to translational cancer research focused on bringing new biomarkers and novel therapies into the clinic. He enjoys teaching, clinical work, serving on review panels, editorial boards (including as Founding Editor-in-Chief of Cancer Biology and Therapy since 2001 http://www.landesbioscience.com/journals/cbt) and training future scientists and clinicians. Dr. El-Deiry is a member of the American Society for Clinical Investigation, the American Association for Cancer Research, the American Society for Clinical Oncology, the Interurban Clinical Club, and the Association of American Physicians.


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS. The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget. 2014 Dec 30; 5(24):12728-37.
    View in: PubMed
  2. Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ. 2015 Jan; 22(1):58-73.
    View in: PubMed
  3. Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, Knight SC, Yagita H, McCaffrey JC, Antonia S, Hockstein N, Witt R, Masters G, Bauer T, Gabrilovich DI. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest. 2014 Jun 2; 124(6):2626-39.
    View in: PubMed
  4. Allen JE, Saroya BS, Kunkel M, Dicker DT, Das A, Peters KL, Joudeh J, Zhu J, El-Deiry WS. Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs. Oncotarget. 2014 Apr 15; 5(7):1753-60.
    View in: PubMed
  5. Allen JE, Patel AS, Prabhu VV, Dicker DT, Sheehan JM, Glantz MJ, El-Deiry WS. COX-2 drives metastatic breast cells from brain lesions into the cerebrospinal fluid and systemic circulation. Cancer Res. 2014 May 1; 74(9):2385-90.
    View in: PubMed
  6. Zhang L, Ren X, Cheng Y, Liu X, Allen JE, Zhang Y, Yuan Y, Huang SY, Yang W, Berg A, Webb BS, Connor J, Liu CG, Lu Z, El-Deiry WS, Yang JM. The NF?B inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype. Cancer Biol Ther. 2014 May; 15(5):602-11.
    View in: PubMed
  7. Li C, Chacko AM, Hu J, Hasegawa K, Swails J, Grasso L, El-Deiry WS, Nicolaides N, Muzykantov VR, Divgi CR, Coukos G. Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model. Cancer Biol Ther. 2014 Apr; 15(4):443-51.
    View in: PubMed
  8. Warfel NA, El-Deiry WS. HIF-1 signaling in drug resistance to chemotherapy. Curr Med Chem. 2014; 21(26):3021-8.
    View in: PubMed
  9. Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr Drug Targets. 2014 Jan; 15(1):80-9.
    View in: PubMed
  10. Kline CL, Schiccitano A, Zhu J, Beachler C, Sheikh H, Harvey HA, Mackley HB, McKenna K, Staveley-O'Carroll K, Poritz L, Messaris E, Stewart D, Sivik J, El-Deiry WS. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens. Clin Colorectal Cancer. 2014 Jun; 13(2):119-26.
    View in: PubMed
  11. Hong B, Prabhu VV, Zhang S, van den Heuvel AP, Dicker DT, Kopelovich L, El-Deiry WS. Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. Cancer Res. 2014 Feb 15; 74(4):1153-65.
    View in: PubMed
  12. Warfel NA, Dolloff NG, Dicker DT, Malysz J, El-Deiry WS. CDK1 stabilizes HIF-1a via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle. 2013 Dec 1; 12(23):3689-701.
    View in: PubMed
  13. Kaifi JT, Kunkel M, Zhu J, Dicker DT, Gusani N, Yang Z, Sarwani NE, Li G, Kimchi ET, Staveley-O'Carroll KF, El-Deiry WS. Circulating tumor cells are associated with diffuse spread in stage IV colorectal cancer patients. Cancer Biol Ther. 2013 Dec; 14(12):1174-81.
    View in: PubMed
  14. Harouaka RA, Zhou MD, Yeh YT, Khan WJ, Das A, Liu X, Christ CC, Dicker DT, Baney TS, Kaifi JT, Belani CP, Truica CI, El-Deiry WS, Allerton JP, Zheng SY. Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells. Clin Chem. 2014 Feb; 60(2):323-33.
    View in: PubMed
  15. Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldenberg D, Smith CD, Humphreys R, El-Deiry WS. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS One. 2013; 8(9):e75414.
    View in: PubMed
  16. El-Deiry WS. Investing in biomedical research is important. Cancer Biol Ther. 2013 Oct 1; 14(10):869-70.
    View in: PubMed
  17. Kline CL, El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel). 2013; 6(8):988-1038.
    View in: PubMed
  18. El-Deiry WS. Welcoming Paul Dent as Assistant Editor-in-Chief of Cancer Biology & Therapy. Cancer Biol Ther. 2013 Sep; 14(9):773.
    View in: PubMed
  19. Finnberg NK, Liu Y, El-Deiry WS. Detection of DSS-induced gastrointestinal mucositis in mice by non-invasive optical near-infrared (NIR) imaging of cathepsin activity. Cancer Biol Ther. 2013 Aug; 14(8):736-41.
    View in: PubMed
  20. Lim B, Scicchitano A, Beachler C, Gusani N, Sarwani N, Yang Z, Staveley-O'Carroll K, Ashkenazi A, Portera C, El-Deiry WS. FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. Cancer Biol Ther. 2013 Aug; 14(8):711-9.
    View in: PubMed
  21. Al-Marrawi MY, Saroya BS, Brennan MC, Yang Z, Dykes TM, El-Deiry WS. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther. 2013 Aug; 14(8):703-10.
    View in: PubMed
  22. Lamparella NE, Saroya BS, Yang Z, Sarwani NE, El-Deiry WS. Contradictory KRAS mutation test results in a patient with metastatic colon cancer: a clinical dilemma in the era of personalized medicine. Cancer Biol Ther. 2013 Aug; 14(8):699-702.
    View in: PubMed
  23. Gallant JN, Matthew EM, Cheng H, Harouaka R, Lamparella NE, Kunkel M, Yang Z, Harvey HA, Cream LV, Kumar SM, Robertson GP, Zheng S, Drabick JJ, Truica CI, El-Deiry WS. Predicting therapy response in live tumor cells isolated with the flexible micro spring array device. Cell Cycle. 2013 Jul 1; 12(13):2132-43.
    View in: PubMed
  24. Allen JE, Gallant JN, Dicker DT, Amin S, Irby RB, Sharma AK, El-Deiry WS. The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer. PLoS One. 2013; 8(3):e59380.
    View in: PubMed
  25. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 6; 5(171):171ra17.
    View in: PubMed
  26. Allen JE, El-Deiry WS. Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on ß-catenin. Oncotarget. 2013 Feb; 4(2):184-91.
    View in: PubMed
  27. El-Deiry WS. Impact of genetic targets on cancer therapy. Forward. Adv Exp Med Biol. 2013; 779:v-vi.
    View in: PubMed
  28. Joudeh J, Allen JE, Das A, Prabhu V, Farbaniec M, Adler J, El-Deiry WS. Novel antineoplastics targeting genetic changes in colorectal cancer. Adv Exp Med Biol. 2013; 779:1-34.
    View in: PubMed
  29. Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 2013 Jan; 25(1):52-8.
    View in: PubMed
  30. Crowder RN, El-Deiry WS. Caspase-8 regulation of TRAIL-mediated cell death. Exp Oncol. 2012 Oct; 34(3):160-4.
    View in: PubMed
  31. Prabhu VV, Allen JE, Hong B, Zhang S, Cheng H, El-Deiry WS. Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opin Ther Targets. 2012 Dec; 16(12):1161-74.
    View in: PubMed
  32. Dolloff NG, Allen JE, Dicker DT, Aqui N, Vogl D, Malysz J, Talamo G, El-Deiry WS. Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Mol Cancer Ther. 2012 Nov; 11(11):2321-30.
    View in: PubMed
  33. Cheng H, Hong B, Zhou L, Allen JE, Tai G, Humphreys R, Dicker DT, Liu YY, El-Deiry WS. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle. 2012 Sep 1; 11(17):3312-23.
    View in: PubMed
  34. Allen JE, El-Deiry WS. Regulation of the human TRAIL gene. Cancer Biol Ther. 2012 Oct; 13(12):1143-51.
    View in: PubMed
  35. Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, Lin B, Renshaw MW, Kretz-Rommel A, El-Deiry WS. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol Cancer Ther. 2012 Oct; 11(10):2087-95.
    View in: PubMed
  36. Prabhu VV, Warfel NA, El-Deiry WS. CTGF-mediated autophagy-senescence transition in tumor stroma promotes anabolic tumor growth and metastasis. Cell Cycle. 2012 Jul 15; 11(14):2592-3.
    View in: PubMed
  37. Zhou L, El-Deiry W, Wang W, Ingram ME, Katz SI. Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma. Oncol Rep. 2012 Sep; 28(3):883-8.
    View in: PubMed
  38. Mao X, Nawaz AA, Lin SC, Lapsley MI, Zhao Y, McCoy JP, El-Deiry WS, Huang TJ. An integrated, multiparametric flow cytometry chip using "microfluidic drifting" based three-dimensional hydrodynamic focusing. Biomicrofluidics. 2012 Jun; 6(2):24113-241139.
    View in: PubMed
  39. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Bánhegyi G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahová M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronjé MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, Díaz-Araya G, Díaz-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Farré JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, Fésüs L, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544.
    View in: PubMed
  40. Finnberg NK, Hart LS, Dolloff NG, Rodgers ZB, Dicker DT, El-Deiry WS. High-resolution imaging and antitumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors. Am J Pathol. 2011 Nov; 179(5):2169-76.
    View in: PubMed
  41. Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, El-Deiry WS. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget. 2011 Oct; 2(10):752-60.
    View in: PubMed
  42. Kline CL, Sheikh HS, Scicchitano A, Gingrich R, Beachler C, Finnberg NK, Liao J, Sivik J, El-Deiry WS. Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. Cancer Biol Ther. 2011 Oct 1; 12(7):557-68.
    View in: PubMed
  43. Cazanave SC, Mott JL, Bronk SF, Werneburg NW, Fingas CD, Meng XW, Finnberg N, El-Deiry WS, Kaufmann SH, Gores GJ. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem. 2011 Nov 11; 286(45):39336-48.
    View in: PubMed
  44. Dolloff NG, Ma X, Dicker DT, Humphreys RC, Li LZ, El-Deiry WS. Spectral imaging-based methods for quantifying autophagy and apoptosis. Cancer Biol Ther. 2011 Aug 15; 12(4):349-56.
    View in: PubMed
  45. Dicker DT, Kahn N, Flaherty KT, Lerner J, El-Deiry WS. Hyperspectral imaging: a non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitor. Cancer Biol Ther. 2011 Aug 15; 12(4):326-34.
    View in: PubMed
  46. Zhou L, Wang W, Dicker DT, Humphreys RC, El-Deiry WS. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction. Cancer Biol Ther. 2011 Aug 15; 12(4):335-48.
    View in: PubMed
  47. Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG, Navaraj A, El-Deiry WS. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther. 2011 Aug 1; 12(3):239-51.
    View in: PubMed
  48. Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, El-Deiry WS. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther. 2011 Aug 1; 12(3):229-38.
    View in: PubMed
  49. Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen JG, Grimberg A, El-Deiry WS. Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle. 2011 Jul 15; 10(14):2331-8.
    View in: PubMed
  50. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, Gottlieb E, Green DR, Hengartner MO, Kepp O, Knight RA, Kumar S, Lipton SA, Lu X, Madeo F, Malorni W, Mehlen P, Nuñez G, Peter ME, Piacentini M, Rubinsztein DC, Shi Y, Simon HU, Vandenabeele P, White E, Yuan J, Zhivotovsky B, Melino G, Kroemer G. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012 Jan; 19(1):107-20.
    View in: PubMed
  51. Kuribayashi K, Finnberg N, Jeffers JR, Zambetti GP, El-Deiry WS. The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle. 2011 Jul 15; 10(14):2380-9.
    View in: PubMed
  52. Allen JE, El-Deiry WS. Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation. Gastroenterology. 2011 Aug; 141(2):430-4.
    View in: PubMed
  53. Dolloff NG, Mayes PA, Hart LS, Dicker DT, Humphreys R, El-Deiry WS. Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med. 2011 Jun 8; 3(86):86ra50.
    View in: PubMed
  54. Mayes PA, Dolloff NG, Daniel CJ, Liu JJ, Hart LS, Kuribayashi K, Allen JE, Jee DI, Dorsey JF, Liu YY, Dicker DT, Brown JM, Furth EE, Klein PS, Sears RC, El-Deiry WS. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3ß and CDK1. Cancer Res. 2011 Aug 1; 71(15):5265-75.
    View in: PubMed
  55. Katz SI, Zhou L, Ferrara TA, Wang W, Mayes PA, Smith CD, El-Deiry WS. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. Int J Oncol. 2011 Jul; 39(1):91-100.
    View in: PubMed
  56. Zhang H, Qiao H, Bakken A, Gao F, Huang B, Liu YY, El-Deiry W, Ferrari VA, Zhou R. Utility of dual-modality bioluminescence and MRI in monitoring stem cell survival and impact on post myocardial infarct remodeling. Acad Radiol. 2011 Jan; 18(1):3-12.
    View in: PubMed
  57. Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, Furth E, Enders GH, El-Deiry W, Schelter JM, Cleary MA, Thomas-Tikhonenko A. The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res. 2010 Oct 15; 70(20):8233-46.
    View in: PubMed
  58. Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets. 2010 Oct; 14(10):1091-108.
    View in: PubMed
  59. McGovern PE, Christofidou-Solomidou M, Wang W, Dukes F, Davidson T, El-Deiry WS. Anticancer activity of botanical compounds in ancient fermented beverages (review). Int J Oncol. 2010 Jul; 37(1):5-14.
    View in: PubMed
  60. El-Deiry WS. Funding the marathon: investigators need more than basic experiments and clinical trials to advance the war on cancer. Cancer Biol Ther. 2010 May 15; 9(10):751-3.
    View in: PubMed
  61. Chen F, Wang W, El-Deiry WS. Current strategies to target p53 in cancer. Biochem Pharmacol. 2010 Sep 1; 80(5):724-30.
    View in: PubMed
  62. Matthew EM, Hart LS, Astrinidis A, Navaraj A, Dolloff NG, Dicker DT, Henske EP, El-Deiry WS. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle. 2009 Dec 15; 8(24):4168-75.
    View in: PubMed
  63. Navaraj A, Finnberg N, Dicker DT, Yang W, Matthew EM, El-Deiry WS. Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras. Cancer Biol Ther. 2009 Dec; 8(24):2417-44.
    View in: PubMed
  64. Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W, Dicker DT, El-Deiry WS. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol Ther. 2009 Dec; 8(24):2406-16.
    View in: PubMed
  65. Dorsey JF, Mintz A, Tian X, Dowling ML, Plastaras JP, Dicker DT, Kao GD, El-Deiry WS. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Mol Cancer Ther. 2009 Dec; 8(12):3285-95.
    View in: PubMed
  66. Allen JE, Hart LS, Dicker DT, Wang W, El-Deiry WS. Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol Ther. 2009 Nov; 8(22):2194-205.
    View in: PubMed
  67. Huang C, Zhang XM, Tavaluc RT, Hart LS, Dicker DT, Wang W, El-Deiry WS. The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biol Ther. 2009 Nov; 8(22):2186-93.
    View in: PubMed
  68. Ide T, Brown-Endres L, Chu K, Ongusaha PP, Ohtsuka T, El-Deiry WS, Aaronson SA, Lee SW. GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress. Mol Cell. 2009 Nov 13; 36(3):379-92.
    View in: PubMed
  69. Zhou L, El-Deiry WS. Multispectral fluorescence imaging. J Nucl Med. 2009 Oct; 50(10):1563-6.
    View in: PubMed
  70. Wambi CO, Sanzari JK, Sayers CM, Nuth M, Zhou Z, Davis J, Finnberg N, Lewis-Wambi JS, Ware JH, El-Deiry WS, Kennedy AR. Protective effects of dietary antioxidants on proton total-body irradiation-mediated hematopoietic cell and animal survival. Radiat Res. 2009 Aug; 172(2):175-86.
    View in: PubMed
  71. Hart LS, El-Deiry WS. Cell death: a new Par-4 the TRAIL. Cell. 2009 Jul 23; 138(2):220-2.
    View in: PubMed
  72. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Castedo M, Cidlowski JA, Ciechanover A, Cohen GM, De Laurenzi V, De Maria R, Deshmukh M, Dynlacht BD, El-Deiry WS, Flavell RA, Fulda S, Garrido C, Golstein P, Gougeon ML, Green DR, Gronemeyer H, Hajnóczky G, Hardwick JM, Hengartner MO, Ichijo H, Jäättelä M, Kepp O, Kimchi A, Klionsky DJ, Knight RA, Kornbluth S, Kumar S, Levine B, Lipton SA, Lugli E, Madeo F, Malomi W, Marine JC, Martin SJ, Medema JP, Mehlen P, Melino G, Moll UM, Morselli E, Nagata S, Nicholson DW, Nicotera P, Nuñez G, Oren M, Penninger J, Pervaiz S, Peter ME, Piacentini M, Prehn JH, Puthalakath H, Rabinovich GA, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Scorrano L, Simon HU, Steller H, Tschopp J, Tsujimoto Y, Vandenabeele P, Vitale I, Vousden KH, Youle RJ, Yuan J, Zhivotovsky B, Kroemer G. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 2009 Aug; 16(8):1093-107.
    View in: PubMed
  73. Lu C, El-Deiry WS. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis. 2009 Apr; 14(4):597-606.
    View in: PubMed
  74. Finnberg N, Wambi C, Ware JH, Kennedy AR, El-Deiry WS. Gamma-radiation (GR) triggers a unique gene expression profile associated with cell death compared to proton radiation (PR) in mice in vivo. Cancer Biol Ther. 2008 Dec; 7(12):2023-33.
    View in: PubMed
  75. Lu C, Wang W, El-Deiry WS. Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73. Cancer Biol Ther. 2008 Dec; 7(12):2039-46.
    View in: PubMed
  76. Plastaras JP, Dorsey JF, Carroll K, Kim SH, Birnbaum MJ, El-Deiry WS. Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biol Ther. 2008 Dec; 7(12):2047-53.
    View in: PubMed
  77. Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther. 2008 Dec; 7(12):2034-8.
    View in: PubMed
  78. Bassett EA, Wang W, Rastinejad F, El-Deiry WS. Structural and functional basis for therapeutic modulation of p53 signaling. Clin Cancer Res. 2008 Oct 15; 14(20):6376-86.
    View in: PubMed
  79. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nuñez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009 Jan; 16(1):3-11.
    View in: PubMed
  80. Mayes P, Dicker D, Liu Y, El-Deiry W. Noninvasive vascular imaging in fluorescent tumors using multispectral unmixing. Biotechniques. 2008 Oct; 45(4):459-60, 461-4.
    View in: PubMed
  81. Hart LS, El-Deiry WS. Invincible, but not invisible: imaging approaches toward in vivo detection of cancer stem cells. J Clin Oncol. 2008 Jun 10; 26(17):2901-10.
    View in: PubMed
  82. Liao W, Xiao Q, Tchikov V, Fujita K, Yang W, Wincovitch S, Garfield S, Conze D, El-Deiry WS, Schütze S, Srinivasula SM. CARP-2 is an endosome-associated ubiquitin ligase for RIP and regulates TNF-induced NF-kappaB activation. Curr Biol. 2008 May 6; 18(9):641-9.
    View in: PubMed
  83. Kim M, Liao J, Dowling ML, Voong KR, Parker SE, Wang S, El-Deiry WS, Kao GD. TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells. Cancer Res. 2008 May 1; 68(9):3440-9.
    View in: PubMed
  84. Kim SH, Ricci MS, El-Deiry WS. Mcl-1: a gateway to TRAIL sensitization. Cancer Res. 2008 Apr 1; 68(7):2062-4.
    View in: PubMed
  85. Finnberg N, El-Deiry WS. TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle. 2008 Jun 1; 7(11):1525-8.
    View in: PubMed
  86. Noma K, Smalley KS, Lioni M, Naomoto Y, Tanaka N, El-Deiry W, King AJ, Nakagawa H, Herlyn M. The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology. 2008 Jun; 134(7):1981-93.
    View in: PubMed
  87. Laguinge LM, Samara RN, Wang W, El-Deiry WS, Corner G, Augenlicht L, Mishra L, Jessup JM. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Res. 2008 Feb 1; 68(3):909-17.
    View in: PubMed
  88. Yang W, Dolloff NG, El-Deiry WS. ERK and MDM2 prey on FOXO3a. Nat Cell Biol. 2008 Feb; 10(2):125-6.
    View in: PubMed
  89. Yang W, Dicker DT, Chen J, El-Deiry WS. CARPs enhance p53 turnover by degrading 14-3-3sigma and stabilizing MDM2. Cell Cycle. 2008 Mar 1; 7(5):670-82.
    View in: PubMed
  90. Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest. 2008 Jan; 118(1):111-23.
    View in: PubMed
  91. Kuribayashi K, Finnberg N, El-Deiry WS. Studying p53-dependent cell death in vitro and in vivo. Methods Enzymol. 2008; 446:159-73.
    View in: PubMed
  92. Kuribayashi K, El-Deiry WS. Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol. 2008; 615:201-21.
    View in: PubMed
  93. Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. Curr Opin Oncol. 2008 Jan; 20(1):90-6.
    View in: PubMed
  94. El-Deiry WS. Targeting mutant p53 shows promise for sunscreens and skin cancer. J Clin Invest. 2007 Dec; 117(12):3658-60.
    View in: PubMed
  95. Corn PG, El-Deiry WS. Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage. Cancer Biol Ther. 2007 Dec; 6(12):1858-66.
    View in: PubMed
  96. Okawa T, Michaylira CZ, Kalabis J, Stairs DB, Nakagawa H, Andl CD, Johnstone CN, Klein-Szanto AJ, El-Deiry WS, Cukierman E, Herlyn M, Rustgi AK. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev. 2007 Nov 1; 21(21):2788-803.
    View in: PubMed
  97. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK, Diehl JA, Smith CD, Flaherty KT, El-Deiry WS. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 2007 Oct 1; 67(19):9443-54.
    View in: PubMed
  98. Matthew EM, Yen TJ, Dicker DT, Dorsey JF, Yang W, Navaraj A, El-Deiry WS. Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle. 2007 Oct 15; 6(20):2571-8.
    View in: PubMed
  99. Wang S, Mintz A, Mochizuki K, Dorsey JF, Ackermann JM, Alavi A, El-Deiry WS. Multimodality optical imaging and 18F-FDG uptake in wild-type p53-containing and p53-null human colon tumor xenografts. Cancer Biol Ther. 2007 Oct; 6(10):1649-53.
    View in: PubMed
  100. Yang W, El-Deiry WS. CARPs are E3 ligases that target apical caspases and p53. Cancer Biol Ther. 2007 Nov; 6(11):1676-83.
    View in: PubMed
  101. Maniar TN, Braunstein I, Keefe S, Hussen S, Abrams T, De Michele A, El-Deiry WS. Childhood ALL and second neoplasms. Cancer Biol Ther. 2007 Oct; 6(10):1525-31.
    View in: PubMed
  102. Tavaluc RT, Hart LS, Dicker DT, El-Deiry WS. Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle. 2007 Oct 15; 6(20):2554-62.
    View in: PubMed
  103. Dicker DT, Lerner JM, El-Deiry WS. Hyperspectral image analysis of live cells in various cell cycle stages. Cell Cycle. 2007 Oct 15; 6(20):2563-70.
    View in: PubMed
  104. Sussman RT, Ricci MS, Hart LS, Sun SY, El-Deiry WS. Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther. 2007 Sep; 6(9):1490-5.
    View in: PubMed
  105. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD, El-Deiry WS. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell. 2007 Jul; 12(1):66-80.
    View in: PubMed
  106. Takaoka M, Kim SH, Okawa T, Michaylira CZ, Stairs DB, Johnstone CN, Andl CD, Rhoades B, Lee JJ, Klein-Szanto AJ, El-Deiry WS, Nakagawa H. IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms. Cancer Biol Ther. 2007 Apr; 6(4):534-40.
    View in: PubMed
  107. Tumeh PC, Lerner JM, Dicker DT, El-Deiry WS. Differentiation of vascular and non-vascular skin spectral signatures using in vivo hyperspectral radiometric imaging: implications for monitoring angiogenesis. Cancer Biol Ther. 2007 Mar; 6(3):447-53.
    View in: PubMed
  108. Lioni M, Brafford P, Andl C, Rustgi A, El-Deiry W, Herlyn M, Smalley KS. Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. Am J Pathol. 2007 Feb; 170(2):709-21.
    View in: PubMed
  109. Scata KA, El-Deiry WS. p53, BRCA1 and breast Cancer chemoresistance. Adv Exp Med Biol. 2007; 608:70-86.
    View in: PubMed
  110. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007; 3(1):1-33.
    View in: PubMed
  111. Yang W, Rozan LM, McDonald ER, Navaraj A, Liu JJ, Matthew EM, Wang W, Dicker DT, El-Deiry WS. CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J Biol Chem. 2007 Feb 2; 282(5):3273-81.
    View in: PubMed
  112. Kim SH, Nakagawa H, Navaraj A, Naomoto Y, Klein-Szanto AJ, Rustgi AK, El-Deiry WS. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Res. 2006 Nov 1; 66(21):10415-24.
    View in: PubMed
  113. Grimberg A, Coleman CM, Shi Z, Burns TF, MacLachlan TK, Wang W, El-Deiry WS. Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling. Cancer Biol Ther. 2006 Oct; 5(10):1408-14.
    View in: PubMed
  114. Rozan LM, El-Deiry WS. p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ. 2007 Jan; 14(1):3-9.
    View in: PubMed
  115. Oyama K, Okawa T, Nakagawa H, Takaoka M, Andl CD, Kim SH, Klein-Szanto A, Diehl JA, Herlyn M, El-Deiry W, Rustgi AK. AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture. Oncogene. 2007 Apr 5; 26(16):2353-64.
    View in: PubMed
  116. Scata KA, El-Deiry WS. Taming NEMO to slay cancer cells. Cancer Biol Ther. 2006 Sep; 5(9):1096-7.
    View in: PubMed
  117. Rozan LM, El-Deiry WS. Identification and characterization of proteins interacting with Traf4, an enigmatic p53 target. Cancer Biol Ther. 2006 Sep; 5(9):1228-35.
    View in: PubMed
  118. Jin Z, El-Deiry WS. Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol Cell Biol. 2006 Nov; 26(21):8136-48.
    View in: PubMed
  119. Dicker DT, Lerner J, Van Belle P, Barth SF, Guerry D, Herlyn M, Elder DE, El-Deiry WS. Differentiation of normal skin and melanoma using high resolution hyperspectral imaging. Cancer Biol Ther. 2006 Aug; 5(8):1033-8.
    View in: PubMed
  120. Kuribayashi K, Mayes PA, El-Deiry WS. What are caspases 3 and 7 doing upstream of the mitochondria? Cancer Biol Ther. 2006 Jul; 5(7):763-5.
    View in: PubMed
  121. Tang J, Qu LK, Zhang J, Wang W, Michaelson JS, Degenhardt YY, El-Deiry WS, Yang X. Critical role for Daxx in regulating Mdm2. Nat Cell Biol. 2006 Aug; 8(8):855-62.
    View in: PubMed
  122. Finnberg N, El-Deiry WS. Selective TRAIL-induced apoptosis in dysplastic neoplasia of the colon may lead to new neoadjuvant or adjuvant therapies. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4132-6.
    View in: PubMed
  123. Wang S, El-Deiry WS. p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res. 2006 Jul 15; 66(14):6982-9.
    View in: PubMed
  124. Wang W, Kim SH, El-Deiry WS. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci U S A. 2006 Jul 18; 103(29):11003-8.
    View in: PubMed
  125. El-Deiry WS, Sigman CC, Kelloff GJ. Imaging and oncologic drug development. J Clin Oncol. 2006 Jul 10; 24(20):3261-73.
    View in: PubMed
  126. Mayes PA, El-Deiry WS. The complementary roles of the extrinsic and intrinsic apoptotic pathways in promoting the death of cancer cells. Cancer J. 2006 Jul-Aug; 12(4):247-9.
    View in: PubMed
  127. El-Deiry WS. Lobbying Congress to make cancer funding a priority: what scientists can do. Cancer Biol Ther. 2006 May; 5(5):467-9.
    View in: PubMed
  128. Navaraj A, Mori T, El-Deiry WS. Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers. Cancer Biol Ther. 2005 Dec; 4(12):1409-14.
    View in: PubMed
  129. Corn PG, Ricci MS, Scata KA, Arsham AM, Simon MC, Dicker DT, El-Deiry WS. Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther. 2005 Nov; 4(11):1285-94.
    View in: PubMed
  130. Kroemer G, El-Deiry WS, Golstein P, Peter ME, Vaux D, Vandenabeele P, Zhivotovsky B, Blagosklonny MV, Malorni W, Knight RA, Piacentini M, Nagata S, Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ. 2005 Nov; 12 Suppl 2:1463-7.
    View in: PubMed
  131. Mayes PA, Campbell L, Ricci MS, Plastaras JP, Dicker DT, El-Deiry WS. Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biol Ther. 2005 Oct; 4(10):1068-74.
    View in: PubMed
  132. Takaoka M, Smith CE, Mashiba MK, Okawa T, Andl CD, El-Deiry WS, Nakagawa H. EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. Am J Physiol Gastrointest Liver Physiol. 2006 Feb; 290(2):G404-16.
    View in: PubMed
  133. Finnberg N, Kim SH, Furth EE, Liu JJ, Russo P, Piccoli DA, Grimberg A, El-Deiry WS. Non-invasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-Fluorouracil, CPT-11 and/or TRAIL. Cancer Biol Ther. 2005 Sep; 4(9):937-42.
    View in: PubMed
  134. Wang J, Devgan V, Corrado M, Prabhu NS, El-Deiry WS, Riccardi C, Pandolfi PP, Missero C, Dotto GP. Glucocorticoid-induced tumor necrosis factor receptor is a p21Cip1/WAF1 transcriptional target conferring resistance of keratinocytes to UV light-induced apoptosis. J Biol Chem. 2005 Nov 11; 280(45):37725-31.
    View in: PubMed
  135. Dicker DT, Kim SH, Jin Z, El-Deiry WS. Heterogeneity in non-invasive detection of apoptosis among human tumor cell lines using annexin-V tagged with EGFP or Qdot-705. Cancer Biol Ther. 2005 Sep; 4(9):1014-7.
    View in: PubMed
  136. Wang W, Ho WC, Dicker DT, MacKinnon C, Winkler JD, Marmorstein R, El-Deiry WS. Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther. 2005 Aug; 4(8):893-8.
    View in: PubMed
  137. Liu JJ, Wang W, Dicker DT, El-Deiry WS. Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin. Cancer Biol Ther. 2005 Aug; 4(8):885-92.
    View in: PubMed
  138. El-Deiry WS. Plagiarism is not acceptable in science or for cancer biology & therapy. Cancer Biol Ther. 2005 Jun; 4(6):619-20.
    View in: PubMed
  139. El-Deiry WS. Meeting report: The international conference on tumor progression and therapeutic resistance. Cancer Res. 2005 Jun 1; 65(11):4475-84.
    View in: PubMed
  140. Dash BC, El-Deiry WS. Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol. 2005 Apr; 25(8):3364-87.
    View in: PubMed
  141. Grimberg A, Coleman CM, Burns TF, Himelstein BP, Koch CJ, Cohen P, El-Deiry WS. p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J Clin Endocrinol Metab. 2005 Jun; 90(6):3568-74.
    View in: PubMed
  142. Finnberg N, Gruber JJ, Fei P, Rudolph D, Bric A, Kim SH, Burns TF, Ajuha H, Page R, Wu GS, Chen Y, McKenna WG, Bernhard E, Lowe S, Mak T, El-Deiry WS. DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol. 2005 Mar; 25(5):2000-13.
    View in: PubMed
  143. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005 Feb; 4(2):139-63.
    View in: PubMed
  144. Lin SW, Cook M, Finnberg N, Bernhard E, Baldwin D, El-Deiry WS. p53-dependent induction of serine proteases in irradiated mouse colon. Cancer Biol Ther. 2004 Dec; 3(12):1290-7.
    View in: PubMed
  145. Fei P, Wang W, Kim SH, Wang S, Burns TF, Sax JK, Buzzai M, Dicker DT, McKenna WG, Bernhard EJ, El-Deiry WS. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell. 2004 Dec; 6(6):597-609.
    View in: PubMed
  146. Tibbetts MD, Shiozaki EN, Gu L, McDonald ER, El-Deiry WS, Shi Y. Crystal structure of a FYVE-type zinc finger domain from the caspase regulator CARP2. Structure. 2004 Dec; 12(12):2257-63.
    View in: PubMed
  147. Takaoka M, Harada H, Andl CD, Oyama K, Naomoto Y, Dempsey KL, Klein-Szanto AJ, El-Deiry WS, Grimberg A, Nakagawa H. Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res. 2004 Nov 1; 64(21):7711-23.
    View in: PubMed
  148. Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, El-Deiry WS. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol. 2004 Oct; 24(19):8541-55.
    View in: PubMed
  149. Shah R, El-Deiry WS. p53-Dependent activation of a molecular beacon in tumor cells following exposure to doxorubicin chemotherapy. Cancer Biol Ther. 2004 Sep; 3(9):871-5.
    View in: PubMed
  150. Wang S, El-Deiry WS. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res. 2004 Sep 15; 64(18):6666-72.
    View in: PubMed
  151. Gruber PJ, Li Z, Li H, Worrad D, Huang B, Abdullah I, Wang W, El-Deiry W, Ferrari VA, Zhou R. In vivo imaging of MLC2v-luciferase, a cardiac-specific reporter gene expression in mice. Acad Radiol. 2004 Sep; 11(9):1022-8.
    View in: PubMed
  152. Wang W, El-Deiry WS. Targeting p53 by PTD-mediated transduction. Trends Biotechnol. 2004 Sep; 22(9):431-4.
    View in: PubMed
  153. Finnberg N, El-Deiry WS. Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: an effective multi-faceted targeting of the tumor-cell phenotype? Cancer Biol Ther. 2004 Jul; 3(7):614-6.
    View in: PubMed
  154. Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK, Chen Y, El-Deiry WS. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem. 2004 Sep 17; 279(38):40044-52.
    View in: PubMed
  155. Scata KA, El-Deiry WS. Zebrafish: swimming towards a role for fanconi genes in DNA repair. Cancer Biol Ther. 2004 Jun; 3(6):501-2.
    View in: PubMed
  156. Jin Z, McDonald ER, Dicker DT, El-Deiry WS. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem. 2004 Aug 20; 279(34):35829-39.
    View in: PubMed
  157. Kim K, Nakagawa H, Fei P, Rustgi AK, El-Deiry WS. Targeting Bcl-xL in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9. Cell Death Differ. 2004 May; 11(5):583-7.
    View in: PubMed
  158. Thomas-Tikhonenko A, Viard-Leveugle I, Dews M, Wehrli P, Sevignani C, Yu D, Ricci S, el-Deiry W, Aronow B, Kaya G, Saurat JH, French LE. Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Res. 2004 May 1; 64(9):3126-36.
    View in: PubMed
  159. McDonald ER, El-Deiry WS. Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proc Natl Acad Sci U S A. 2004 Apr 20; 101(16):6170-5.
    View in: PubMed
  160. Wang S, El-Deiry WS. Cytochrome c: a crosslink between the mitochondria and the endoplasmic reticulum in calcium-dependent apoptosis. Cancer Biol Ther. 2004 Jan; 3(1):44-6.
    View in: PubMed
  161. Wang S, El-Deiry WS. The p53 pathway: targets for the development of novel cancer therapeutics. Cancer Treat Res. 2004; 119:175-87.
    View in: PubMed
  162. Wang W, El-Deiry WS. Targeting FOXO kills two birds with one stone. Chem Biol. 2004 Jan; 11(1):16-8.
    View in: PubMed
  163. Dash BC, El-Deiry WS. Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol Biol. 2004; 280:99-161.
    View in: PubMed
  164. Wang S, El-Deiry WS. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A. 2003 Dec 9; 100(25):15095-100.
    View in: PubMed
  165. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003 Nov 24; 22(53):8628-33.
    View in: PubMed
  166. Das S, El-Deiry WS, Somasundaram K. Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73beta. Oncogene. 2003 Nov 20; 22(52):8394-402.
    View in: PubMed
  167. Rikhof B, Corn PG, El-Deiry WS. Caspase 10 levels are increased following DNA damage in a p53-dependent manner. Cancer Biol Ther. 2003 Nov-Dec; 2(6):707-12.
    View in: PubMed
  168. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene. 2003 Oct 20; 22(47):7486-95.
    View in: PubMed
  169. Corn PG, McDonald ER, Herman JG, El-Deiry WS. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genet. 2003 Nov; 35(3):229-37.
    View in: PubMed
  170. Fei P, El-Deiry WS. P53 and radiation responses. Oncogene. 2003 Sep 1; 22(37):5774-83.
    View in: PubMed
  171. Choi EA, Lei H, Maron DJ, Wilson JM, Barsoum J, Fraker DL, El-Deiry WS, Spitz FR. Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. Cancer Res. 2003 Sep 1; 63(17):5299-307.
    View in: PubMed
  172. Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry WS. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol. 2003 Aug; 23(16):5556-71.
    View in: PubMed
  173. Burns TF, El-Deiry WS. Microarray analysis of p53 target gene expression patterns in the spleen and thymus in response to ionizing radiation. Cancer Biol Ther. 2003 Jul-Aug; 2(4):431-43.
    View in: PubMed
  174. Sax JK, Stoddard A, Murphy ME, Chodosh L, El-Deiry WS. Microarray expression profiling of p53-dependent transcriptional changes in an immortalized mouse embryo fibroblast cell line. Cancer Biol Ther. 2003 Jul-Aug; 2(4):416-30.
    View in: PubMed
  175. Wang W, Rastinejad F, El-Deiry WS. Restoring p53-dependent tumor suppression. Cancer Biol Ther. 2003 Jul-Aug; 2(4 Suppl 1):S55-63.
    View in: PubMed
  176. Sax JK, El-Deiry WS. Identification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic gene. J Biol Chem. 2003 Sep 19; 278(38):36435-44.
    View in: PubMed
  177. Campling BG, El-Deiry WS. Clinical implication of p53 mutation in lung cancer. Mol Biotechnol. 2003 Jun; 24(2):141-56.
    View in: PubMed
  178. Benezra M, Chevallier N, Morrison DJ, MacLachlan TK, El-Deiry WS, Licht JD. BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. J Biol Chem. 2003 Jul 18; 278(29):26333-41.
    View in: PubMed
  179. Ozören N, El-Deiry WS. Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol. 2003 Apr; 13(2):135-47.
    View in: PubMed
  180. Gruss CJ, Satyamoorthy K, Berking C, Lininger J, Nesbit M, Schaider H, Liu ZJ, Oka M, Hsu MY, Shirakawa T, Li G, Bogenrieder T, Carmeliet P, El-Deiry WS, Eck SL, Rao JS, Baker AH, Bennet JT, Crombleholme TM, Velazquez O, Karmacharya J, Margolis DJ, Wilson JM, Detmar M, Skobe M, Robbins PD, Buck C, Herlyn M. Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. J Invest Dermatol. 2003 Apr; 120(4):683-92.
    View in: PubMed
  181. Sax JK, El-Deiry WS. p53 downstream targets and chemosensitivity. Cell Death Differ. 2003 Apr; 10(4):413-7.
    View in: PubMed
  182. Das S, El-Deiry WS, Somasundaram K. Regulation of the p53 homolog p73 by adenoviral oncogene E1A. J Biol Chem. 2003 May 16; 278(20):18313-20.
    View in: PubMed
  183. Wang W, El-Deiry WS. Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther. 2003 Mar-Apr; 2(2):196-202.
    View in: PubMed
  184. Wang W, Takimoto R, Rastinejad F, El-Deiry WS. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol. 2003 Mar; 23(6):2171-81.
    View in: PubMed
  185. Ricci MS, El-Deiry WS. DNA footprinting. Methods Mol Biol. 2003; 223:117-27.
    View in: PubMed
  186. Dicker DT, El-Deiry WS. Flow cytometric analysis of cell cycle control by tumor suppressor genes. Methods Mol Biol. 2003; 223:211-5.
    View in: PubMed
  187. Dicker DT, El-Deiry WS. Flow cytometric analysis of tumor suppressor gene-induced apoptosis. Methods Mol Biol. 2003; 223:271-82.
    View in: PubMed
  188. Burns TF, el-Deiry WS. Cell death signaling in maligancy. Cancer Treat Res. 2003; 115:319-43.
    View in: PubMed
  189. Campling BG, el-Deiry WS. Clinical implications of p53 mutations in lung cancer. Methods Mol Med. 2003; 75:53-77.
    View in: PubMed
  190. MacLachlan TK, El-Deiry WS. Analysis of cyclin-dependent kinase activity. Methods Mol Biol. 2003; 223:217-20.
    View in: PubMed
  191. MacLachlan TK, El-Deiry WS. Identification of DNA-binding of tumor suppressor genes by chromatin immunoprecipitation. Methods Mol Biol. 2003; 223:129-33.
    View in: PubMed
  192. Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, Halazonetis TD, El-Deiry WS. Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis. 2003 Jan; 24(1):47-51.
    View in: PubMed
  193. Sax JK, El-Deiry WS. p53-induced gene expression analysis. Methods Mol Biol. 2003; 234:65-71.
    View in: PubMed
  194. McDonald ER, El-Deiry WS. Yeast two-hybrid screening as a means of deciphering tumor suppressor pathways. Methods Mol Biol. 2003; 223:173-85.
    View in: PubMed
  195. Fei P, Bernhard EJ, El-Deiry WS. Tissue-specific induction of p53 targets in vivo. Cancer Res. 2002 Dec 15; 62(24):7316-27.
    View in: PubMed
  196. Ozören N, El-Deiry W. Heat shock protects HCT116 and H460 cells from TRAIL-induced apoptosis. Exp Cell Res. 2002 Dec 10; 281(2):175-81.
    View in: PubMed
  197. Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol. 2002 Nov; 4(11):842-9.
    View in: PubMed
  198. Ozören N, El-Deiry WS. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia. 2002 Nov-Dec; 4(6):551-7.
    View in: PubMed
  199. Venkataramani RN, MacLachlan TK, Chai X, El-Deiry WS, Marmorstein R. Structure-based design of p18INK4c proteins with increased thermodynamic stability and cell cycle inhibitory activity. J Biol Chem. 2002 Dec 13; 277(50):48827-33.
    View in: PubMed
  200. El-Deiry WS. Transactivation of repair genes by BRCA1. Cancer Biol Ther. 2002 Sep-Oct; 1(5):490-1.
    View in: PubMed
  201. Grimberg A, Liu B, Bannerman P, El-Deiry WS, Cohen P. IGFBP-3 mediates p53-induced apoptosis during serum starvation. Int J Oncol. 2002 Aug; 21(2):327-35.
    View in: PubMed
  202. El-Deiry WS. Phenomenology and scientific progress. Cancer Biol Ther. 2002 Jul-Aug; 1(4):436-7.
    View in: PubMed
  203. MacLachlan TK, El-Deiry WS. Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci U S A. 2002 Jul 9; 99(14):9492-7.
    View in: PubMed
  204. MacLachlan TK, Takimoto R, El-Deiry WS. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol. 2002 Jun; 22(12):4280-92.
    View in: PubMed
  205. He Q, Lee DI, Rong R, Yu M, Luo X, Klein M, El-Deiry WS, Huang Y, Hussain A, Sheikh MS. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene. 2002 Apr 18; 21(17):2623-33.
    View in: PubMed
  206. Campbell AM, Campling BG, Algazy KM, el-Deiry WS. Clinical and molecular features of small cell lung cancer. Cancer Biol Ther. 2002 Mar-Apr; 1(2):105-12.
    View in: PubMed
  207. Takimoto R, MacLachlan TK, Dicker DT, Niitsu Y, Mori T, el-Deiry WS. BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. Cancer Biol Ther. 2002 Mar-Apr; 1(2):177-86.
    View in: PubMed
  208. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, el-Deiry WS. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther. 2002 Jan-Feb; 1(1):47-55.
    View in: PubMed
  209. Corn PG, El-Deiry WS. Derangement of growth and differentiation control in oncogenesis. Bioessays. 2002 Jan; 24(1):83-90.
    View in: PubMed
  210. Sax JK, Dash BC, Hong R, Dicker DT, El-Deiry WS. The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression). Cell Cycle. 2002 Jan; 1(1):90-6.
    View in: PubMed
  211. Jin Z, Dicker DT, El-Deiry WS. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle. 2002 Jan; 1(1):82-9.
    View in: PubMed
  212. Wang T, Kobayashi T, Takimoto R, Denes AE, Snyder EL, el-Deiry WS, Brachmann RK. hADA3 is required for p53 activity. EMBO J. 2001 Nov 15; 20(22):6404-13.
    View in: PubMed
  213. El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 2001 Nov; 8(11):1066-75.
    View in: PubMed
  214. Suliman Y, Opitz OG, Avadhani A, Burns TC, El-Deiry W, Wong DT, Rustgi AK. p63 expression is associated with p53 loss in oral-esophageal epithelia of p53-deficient mice. Cancer Res. 2001 Sep 1; 61(17):6467-73.
    View in: PubMed
  215. Higuchi H, Bronk SF, Takikawa Y, Werneburg N, Takimoto R, El-Deiry W, Gores GJ. The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J Biol Chem. 2001 Oct 19; 276(42):38610-8.
    View in: PubMed
  216. Burns TF, El-Deiry WS. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem. 2001 Oct 12; 276(41):37879-86.
    View in: PubMed
  217. Burns TF, Bernhard EJ, El-Deiry WS. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene. 2001 Aug 2; 20(34):4601-12.
    View in: PubMed
  218. Liu Q, El-Deiry WS, Gazitt Y. Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines. Exp Hematol. 2001 Aug; 29(8):962-70.
    View in: PubMed
  219. Fisher MJ, Virmani AK, Wu L, Aplenc R, Harper JC, Powell SM, Rebbeck TR, Sidransky D, Gazdar AF, El-Deiry WS. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res. 2001 Jun; 7(6):1688-97.
    View in: PubMed
  220. El-Deiry WS. Akt takes centre stage in cell-cycle deregulation. Nat Cell Biol. 2001 Mar; 3(3):E71-3.
    View in: PubMed
  221. McDonald ER, El-Deiry WS. Checkpoint genes in cancer. Ann Med. 2001 Mar; 33(2):113-22.
    View in: PubMed
  222. Goldberg GS, Jin Z, Ichikawa H, Naito A, Ohki M, El-Deiry WS, Tsuda H. Global effects of anchorage on gene expression during mammary carcinoma cell growth reveal role of tumor necrosis factor-related apoptosis-inducing ligand in anoikis. Cancer Res. 2001 Feb 15; 61(4):1334-7.
    View in: PubMed
  223. McDonald ER, Chui PC, Martelli PF, Dicker DT, El-Deiry WS. Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling. J Biol Chem. 2001 May 4; 276(18):14939-45.
    View in: PubMed
  224. Kim K, Takimoto R, Dicker DT, Chen Y, Gazitt Y, El-Deiry WS. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. Int J Oncol. 2001 Feb; 18(2):241-7.
    View in: PubMed
  225. Takimoto R, El-Deiry WS. DNA replication blockade impairs p53-transactivation. Proc Natl Acad Sci U S A. 2001 Jan 30; 98(3):781-3.
    View in: PubMed
  226. Meng RD, El-Deiry WS. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp Cell Res. 2001 Jan 15; 262(2):154-69.
    View in: PubMed
  227. Göke R, Göke A, Göke B, El-Deiry WS, Chen Y. Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. Digestion. 2001; 64(2):75-80.
    View in: PubMed
  228. MacLachlan TK, El-Deiry WS. Pointing (zinc) fingers at BRCA1 targets. Nat Med. 2000 Dec; 6(12):1318-9.
    View in: PubMed
  229. Ricci MS, el-Deiry WS. Novel strategies for therapeutic design in molecular oncology using gene expression profiles. Curr Opin Mol Ther. 2000 Dec; 2(6):682-90.
    View in: PubMed
  230. Ozoren N, Kim K, Burns TF, Dicker DT, Moscioni AD, El-Deiry WS. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2000 Nov 15; 60(22):6259-65.
    View in: PubMed
  231. Mitchell KO, Ricci MS, Miyashita T, Dicker DT, Jin Z, Reed JC, El-Deiry WS. Bax is a transcriptional target and mediator of c-myc-induced apoptosis. Cancer Res. 2000 Nov 15; 60(22):6318-25.
    View in: PubMed
  232. MacLachlan TK, Dash BC, Dicker DT, El-Deiry WS. Repression of BRCA1 through a feedback loop involving p53. J Biol Chem. 2000 Oct 13; 275(41):31869-75.
    View in: PubMed
  233. Satyamoorthy K, Chehab NH, Waterman MJ, Lien MC, El-Deiry WS, Herlyn M, Halazonetis TD. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ. 2000 Sep; 11(9):467-74.
    View in: PubMed
  234. El-Deiry W. AACR - 91st meeting. Novel concepts and targets for therapeutic manipulation. IDrugs. 2000 Jul; 3(7):717-8.
    View in: PubMed
  235. Ozören N, Fisher MJ, Kim K, Liu CX, Genin A, Shifman Y, Dicker DT, Spinner NB, Lisitsyn NA, El-Deiry WS. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol. 2000 May; 16(5):917-25.
    View in: PubMed
  236. McDonald ER, El-Deiry WS. Cell cycle control as a basis for cancer drug development (Review). Int J Oncol. 2000 May; 16(5):871-86.
    View in: PubMed
  237. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene. 2000 Mar 30; 19(14):1735-43.
    View in: PubMed
  238. Xu SQ, El-Deiry WS. p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun. 2000 Mar 5; 269(1):179-90.
    View in: PubMed
  239. Kim K, Fisher MJ, Xu SQ, el-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res. 2000 Feb; 6(2):335-46.
    View in: PubMed
  240. Meng RD, McDonald ER, Sheikh MS, Fornace AJ, El-Deiry WS. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther. 2000 Feb; 1(2):130-44.
    View in: PubMed
  241. MacLachlan TK, Somasundaram K, Sgagias M, Shifman Y, Muschel RJ, Cowan KH, El-Deiry WS. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J Biol Chem. 2000 Jan 28; 275(4):2777-85.
    View in: PubMed
  242. Wu GS, Kim K, el-Deiry WS. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Adv Exp Med Biol. 2000; 465:143-51.
    View in: PubMed
  243. Wu GS, Burns TF, McDonald ER, Meng RD, Kao G, Muschel R, Yen T, el-Deiry WS. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene. 1999 Nov 11; 18(47):6411-8.
    View in: PubMed
  244. Somasundaram K, MacLachlan TK, Burns TF, Sgagias M, Cowan KH, Weber BL, el-Deiry WS. BRCA1 signals ARF-dependent stabilization and coactivation of p53. Oncogene. 1999 Nov 11; 18(47):6605-14.
    View in: PubMed
  245. Song S, MacLachlan TK, Meng RD, El-Deiry WS. Comparative gene expression profiling in response to p53 in a human lung cancer cell line. Biochem Biophys Res Commun. 1999 Nov 2; 264(3):891-5.
    View in: PubMed
  246. Burns TF, El-Deiry WS. The p53 pathway and apoptosis. J Cell Physiol. 1999 Nov; 181(2):231-9.
    View in: PubMed
  247. Maclachlan TK, Meng RD, El-Deiry WS. "p53: Twenty Years On" in Trieste, Italy, May 20-22, 1999. J Cell Physiol. 1999 Nov; 181(2):371-4.
    View in: PubMed
  248. Prabhu NS, Somasundaram K, Tian H, Enders GH, Satyamoorthy K, Herlyn M, El-Deiry WS. The administration schedule of cyclin-dependent kinase inhibitor gene therapy and etoposide chemotherapy is a major determinant of cytotoxicity. Int J Oncol. 1999 Aug; 15(2):209-16.
    View in: PubMed
  249. Sheikh MS, Huang Y, Fernandez-Salas EA, El-Deiry WS, Friess H, Amundson S, Yin J, Meltzer SJ, Holbrook NJ, Fornace AJ. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene. 1999 Jul 15; 18(28):4153-9.
    View in: PubMed
  250. Wu GS, Burns TF, Zhan Y, Alnemri ES, El-Deiry WS. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 1999 Jun 15; 59(12):2770-5.
    View in: PubMed
  251. Sun SY, Yue P, Wu GS, El-Deiry WS, Shroot B, Hong WK, Lotan R. Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res. 1999 Jun 15; 59(12):2829-33.
    View in: PubMed
  252. Mitra J, Dai CY, Somasundaram K, El-Deiry WS, Satyamoorthy K, Herlyn M, Enders GH. Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a). Mol Cell Biol. 1999 May; 19(5):3916-28.
    View in: PubMed
  253. Yang WL, Zeng YX, El-Deiry WS, Nason-Burchenal K, Dmitrovsky E, Chin KV. Transcriptional activation of the cyclin-dependent kinase inhibitor p21 by PML/RARalpha. Mol Cell Biol Res Commun. 1999 May; 1(2):125-31.
    View in: PubMed
  254. Sun SY, Yue P, Wu GS, El-Deiry WS, Shroot B, Hong WK, Lotan R. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene. 1999 Apr 8; 18(14):2357-65.
    View in: PubMed
  255. Mitchell KO, El-Deiry WS. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ. 1999 Apr; 10(4):223-30.
    View in: PubMed
  256. Meng RD, Phillips P, El-Deiry WS. p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin. Int J Oncol. 1999 Jan; 14(1):5-14.
    View in: PubMed
  257. Ravi R, Mookerjee B, van Hensbergen Y, Bedi GC, Giordano A, El-Deiry WS, Fuchs EJ, Bedi A. p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res. 1998 Oct 15; 58(20):4531-6.
    View in: PubMed
  258. Pai SI, Wu GS, Ozören N, Wu L, Jen J, Sidransky D, El-Deiry WS. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res. 1998 Aug 15; 58(16):3513-8.
    View in: PubMed
  259. Prabhu NS, Somasundaram K, Satyamoorthy K, Herlyn M, El-Deiry WS. p73beta, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int J Oncol. 1998 Jul; 13(1):5-9.
    View in: PubMed
  260. Bennett WP, el-Deiry WS, Rush WL, Guinee DG, Freedman AN, Caporaso NE, Welsh JA, Jones RT, Borkowski A, Travis WD, Fleming MV, Trastek V, Pairolero PC, Tazelaar HD, Midthun D, Jett JR, Liotta LA, Harris CC. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res. 1998 Jun; 4(6):1499-506.
    View in: PubMed
  261. Tong B, Grimes HL, Yang TY, Bear SE, Qin Z, Du K, El-Deiry WS, Tsichlis PN. The Gfi-1B proto-oncoprotein represses p21WAF1 and inhibits myeloid cell differentiation. Mol Cell Biol. 1998 May; 18(5):2462-73.
    View in: PubMed
  262. Wu GS, Saftig P, Peters C, El-Deiry WS. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene. 1998 Apr 30; 16(17):2177-83.
    View in: PubMed
  263. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, Fornace AJ, el-Deiry WS. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 1998 Apr 15; 58(8):1593-8.
    View in: PubMed
  264. Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi D, Weber BL, El-Deiry WS. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene. 1998 Apr 2; 16(13):1713-21.
    View in: PubMed
  265. Yeh WC, de la Pompa JL, McCurrach ME, Shu HB, Elia AJ, Shahinian A, Ng M, Wakeham A, Khoo W, Mitchell K, El-Deiry WS, Lowe SW, Goeddel DV, Mak TW. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science. 1998 Mar 20; 279(5358):1954-8.
    View in: PubMed
  266. Blagosklonny MV, El-Deiry WS. Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer. 1998 Mar 16; 75(6):933-40.
    View in: PubMed
  267. Gee MS, Sarkisian CJ, el-Deiry WS. Identification of a novel AP-2 consensus DNA binding site. Biochem Biophys Res Commun. 1998 Feb 4; 243(1):307-16.
    View in: PubMed
  268. el-Deiry WS. p21/p53, cellular growth control and genomic integrity. Curr Top Microbiol Immunol. 1998; 227:121-37.
    View in: PubMed
  269. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol. 1998; 8(5):345-57.
    View in: PubMed
  270. Meng RD, El-Deiry WS. Tumor suppressor gene therapy for cancer: from the bench to the clinic. Drug Resist Updat. 1998; 1(3):205-10.
    View in: PubMed
  271. Meng RD, Shih H, Prabhu NS, George DL, el-Deiry WS. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression. Clin Cancer Res. 1998 Jan; 4(1):251-9.
    View in: PubMed
  272. Wu GS, Burns TF, McDonald ER, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, el-Deiry WS. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 1997 Oct; 17(2):141-3.
    View in: PubMed
  273. Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Zhang H, Wu GS, Licht JD, Weber BL, El-Deiry WS. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature. 1997 Sep 11; 389(6647):187-90.
    View in: PubMed
  274. Zeng YX, Somasundaram K, Prabhu NS, Krishnadasan R, el-Deiry WS. Detection and analysis of living, growth-inhibited mammalian cells following transfection. Biotechniques. 1997 Jul; 23(1):88, 90, 92, 94.
    View in: PubMed
  275. Somasundaram K, El-Deiry WS. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene. 1997 Mar 6; 14(9):1047-57.
    View in: PubMed
  276. Shick L, Carman JH, Choi JK, Somasundaram K, Burrell M, Hill DE, Zeng YX, Wang Y, Wiman KG, Salhany K, Kadesch TR, Monroe JG, Donehower LA, el-Deiry WS. Decreased immunoglobulin deposition in tumors and increased immature B cells in p53-null mice. Cell Growth Differ. 1997 Feb; 8(2):121-31.
    View in: PubMed
  277. Blagosklonny MV, Prabhu NS, El-Deiry WS. Defects in p21WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res. 1997 Jan 15; 57(2):320-5.
    View in: PubMed
  278. Blagosklonny MV, Giannakakou P, el-Deiry WS, Kingston DG, Higgs PI, Neckers L, Fojo T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res. 1997 Jan 1; 57(1):130-5.
    View in: PubMed
  279. el-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol. 1997 Jan; 9(1):79-87.
    View in: PubMed
  280. Zeng YX, Somasundaram K, el-Deiry WS. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet. 1997 Jan; 15(1):78-82.
    View in: PubMed
  281. Blagosklonny MV, Wu GS, Omura S, el-Deiry WS. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun. 1996 Oct 14; 227(2):564-9.
    View in: PubMed
  282. Dowell SP, McGoogan E, Picksley SM, el-Deiry WS, Vogelstein B, Hall PA. Expression of p21waf1/Cip1, MDM2 and p53 in vivo: analysis of cytological preparations. Cytopathology. 1996 Oct; 7(5):340-51.
    View in: PubMed
  283. Gartel AL, Serfas MS, Gartel M, Goufman E, Wu GS, el-Deiry WS, Tyner AL. p21 (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line. Exp Cell Res. 1996 Sep 15; 227(2):171-81.
    View in: PubMed
  284. Blagosklonny MV, el-Deiry WS. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int J Cancer. 1996 Jul 29; 67(3):386-92.
    View in: PubMed
  285. Prabhu NS, Blagosklonny MV, Zeng YX, Wu GS, Waldman T, El-Deiry WS. Suppression of cancer cell growth by adenovirus expressing p21(WAF1/CIP1) deficient in PCNA interaction. Clin Cancer Res. 1996 Jul; 2(7):1221-9.
    View in: PubMed
  286. Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem. 1996 Jun; 42(6 Pt 1):858-68.
    View in: PubMed
  287. McDonald ER, Wu GS, Waldman T, El-Deiry WS. Repair Defect in p21 WAF1/CIP1 -/- human cancer cells. Cancer Res. 1996 May 15; 56(10):2250-5.
    View in: PubMed
  288. Zeng YX, el-Deiry WS. Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene. 1996 Apr 4; 12(7):1557-64.
    View in: PubMed
  289. Wu GS, El-Deiry WS. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res. 1996 Apr; 2(4):623-33.
    View in: PubMed
  290. Baas IO, Offerhaus JA, El-Deiry WS, Wu TC, Hutchins GM, Kasper EK, Baughman KL, Baumgartner WA, Chiou CJ, Hayward GS, Hruban RH. The WAF1-mediated p53 growth-suppressor pathway is intact in the coronary arteries of heart transplant recipients. Hum Pathol. 1996 Apr; 27(4):324-9.
    View in: PubMed
  291. Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 1995 Aug 1; 86(3):1148-58.
    View in: PubMed
  292. el-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 1995 Jul 1; 55(13):2910-9.
    View in: PubMed
  293. da Costa LT, Liu B, el-Deiry W, Hamilton SR, Kinzler KW, Vogelstein B, Markowitz S, Willson JK, de la Chapelle A, Downey KM, et al. Polymerase delta variants in RER colorectal tumours. Nat Genet. 1995 Jan; 9(1):10-1.
    View in: PubMed
  294. Shiohara M, el-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B, Koeffler HP. Absence of WAF1 mutations in a variety of human malignancies. Blood. 1994 Dec 1; 84(11):3781-4.
    View in: PubMed
  295. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath I, Kohn KW, O'Connor PM. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 1994 Nov 15; 54(22):5824-30.
    View in: PubMed
  296. Tokino T, Thiagalingam S, el-Deiry WS, Waldman T, Kinzler KW, Vogelstein B. p53 tagged sites from human genomic DNA. Hum Mol Genet. 1994 Sep; 3(9):1537-42.
    View in: PubMed
  297. Pietenpol JA, Tokino T, Thiagalingam S, el-Deiry WS, Kinzler KW, Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci U S A. 1994 Mar 15; 91(6):1998-2002.
    View in: PubMed
  298. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994 Mar 1; 54(5):1169-74.
    View in: PubMed
  299. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 Nov 19; 75(4):817-25.
    View in: PubMed
  300. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992 Nov 13; 71(4):587-97.
    View in: PubMed
  301. Yen RW, Vertino PM, Nelkin BD, Yu JJ, el-Deiry W, Cumaraswamy A, Lennon GG, Trask BJ, Celano P, Baylin SB. Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Res. 1992 May 11; 20(9):2287-91.
    View in: PubMed
  302. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet. 1992 Apr; 1(1):45-9.
    View in: PubMed
  303. el-Deiry WS, Nelkin BD, Celano P, Yen RW, Falco JP, Hamilton SR, Baylin SB. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci U S A. 1991 Apr 15; 88(8):3470-4.
    View in: PubMed
  304. el-Deiry WS, So AG, Downey KM. Mechanisms of error discrimination by Escherichia coli DNA polymerase I. Biochemistry. 1988 Jan 26; 27(2):546-53.
    View in: PubMed
  305. El-Deiry WS, Downey KM, So AG. Molecular mechanisms of manganese mutagenesis. Proc Natl Acad Sci U S A. 1984 Dec; 81(23):7378-82.
    View in: PubMed
  306. Cupo P, El-Deiry WS, Whitney PL, Awad WM. Stability of acetylated and superguanidinated chymotrypsinogens. Arch Biochem Biophys. 1982 Jul; 216(2):600-4.
    View in: PubMed
  307. Cupo P, El-Deiry W, Whitney PL, Awad WM. Stabilization of proteins by guanidination. J Biol Chem. 1980 Nov 25; 255(22):10828-33.
    View in: PubMed
El-Deiry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_